By Drug Target Review2025-06-02T08:30:26
A new study from the University of Barcelona’s Institute of Neurosciences has discovered a crucial role for the RTP801 protein in astrocytes, potentially making way for future therapies aimed at slowing or reversing cognitive decline.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-30T09:54:00Z
2026-03-27T13:06:00Z
2023-03-07T10:55:58
Sponsored by Agilent
2025-04-22T14:58:00
Sponsored by Takara Bio USA
2025-10-08T14:00:00
Sponsored by Eurofins Discovery
2023-01-06T10:25:33
Sponsored by Leica Microsystems
2025-05-14T14:30:00
Sponsored by Abzena
2023-05-23T11:10:47
Sponsored by NanoTemper Technologies
Site powered by Webvision Cloud